Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer

Figure 5

In vivo efficacy assessment of wt-p53/gemcitabine combination treatment. (a) Volume change as a function of time showing 57.6***, 63.3.7*** and 77.3%*** reduction in tumor growth on day 33 for SH-Gel, SH-Gel-PEG and SH-Gel-PEG-peptide nanoparticle treated tumor respectively. (b) Tumor weights measured at day 33. Results are presented as mean ± SD (n = 6; ***p < 0.001).

Back to article page